Cargando…
A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
BACKGROUND: Eribulin mesylate is a novel, nontaxane, microtubule dynamics inhibitor. In this study, we assessed the efficacy and safety of eribulin versus eribulin plus the oral small-molecule tyrosine kinase inhibitor anlotinib in patients with locally recurrent or metastatic breast cancer. PATIENT...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265607/ https://www.ncbi.nlm.nih.gov/pubmed/37285718 http://dx.doi.org/10.1016/j.esmoop.2023.101563 |
_version_ | 1785058568065515520 |
---|---|
author | Liu, B. Liu, L. Ran, J. Xie, N. Li, J. Xiao, H. Yang, X. Tian, C. Wu, H. Lu, J. Gao, J. Hu, X. Cao, M. Shui, Z. Hu, Z.-Y. Ouyang, Q. |
author_facet | Liu, B. Liu, L. Ran, J. Xie, N. Li, J. Xiao, H. Yang, X. Tian, C. Wu, H. Lu, J. Gao, J. Hu, X. Cao, M. Shui, Z. Hu, Z.-Y. Ouyang, Q. |
author_sort | Liu, B. |
collection | PubMed |
description | BACKGROUND: Eribulin mesylate is a novel, nontaxane, microtubule dynamics inhibitor. In this study, we assessed the efficacy and safety of eribulin versus eribulin plus the oral small-molecule tyrosine kinase inhibitor anlotinib in patients with locally recurrent or metastatic breast cancer. PATIENTS AND METHODS: In this single-center, open-label, phase II clinical study (NCT05206656) conducted in a Chinese hospital, patients with human epidermal growth factor receptor 2 (HER2)-negative, locally recurrent or metastatic breast cancer previously treated with anthracycline- or taxane-based chemotherapy were randomized (1 : 1) to receive eribulin alone or in combination with anlotinib. The primary efficacy endpoint was investigator-assessed progression-free survival (PFS). RESULTS: From June 2020 to April 2022, a total of 80 patients were randomly assigned to either eribulin monotherapy or eribulin plus anlotinib combination therapy, with 40 patients in each group. The data cut-off was 10 August 2022. The median PFS was 3.5 months [95% confidence interval (CI) 2.8-5.5 months] for eribulin and 5.1 months (95% CI 4.5-6.9 months) for eribulin plus anlotinib (hazard ratio = 0.56, 95% CI 0.32-0.98; P = 0.04). The objective response rates were 32.5% versus 52.5% (P = 0.07), respectively, and disease control rates were 67.5% versus 92.5% (P = 0.01), respectively. Patients <50 years of age, with an Eastern Cooperative Oncology Group performance status score of 0, visceral metastasis, number of treatment lines of four or more, hormone receptor negative (triple-negative), and HER2 low expression appeared to benefit more from combined treatment. The most common adverse events in both groups were leukopenia (n = 28, 70.0%, patients in the eribulin monotherapy group versus n = 35, 87.5%, patients in the combination therapy group), aspartate aminotransferase elevations (n = 28, 70.0%, versus n = 35, 87.5%), neutropenia (n = 25, 62.5%, versus n = 31, 77.5%), and alanine aminotransferase elevations (n = 25, 62.5%, versus n = 30, 75.0%). CONCLUSION: Eribulin plus anlotinib can be considered an alternative treatment option for HER2-negative locally advanced or metastatic breast cancer. |
format | Online Article Text |
id | pubmed-10265607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102656072023-06-15 A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer Liu, B. Liu, L. Ran, J. Xie, N. Li, J. Xiao, H. Yang, X. Tian, C. Wu, H. Lu, J. Gao, J. Hu, X. Cao, M. Shui, Z. Hu, Z.-Y. Ouyang, Q. ESMO Open Original Research BACKGROUND: Eribulin mesylate is a novel, nontaxane, microtubule dynamics inhibitor. In this study, we assessed the efficacy and safety of eribulin versus eribulin plus the oral small-molecule tyrosine kinase inhibitor anlotinib in patients with locally recurrent or metastatic breast cancer. PATIENTS AND METHODS: In this single-center, open-label, phase II clinical study (NCT05206656) conducted in a Chinese hospital, patients with human epidermal growth factor receptor 2 (HER2)-negative, locally recurrent or metastatic breast cancer previously treated with anthracycline- or taxane-based chemotherapy were randomized (1 : 1) to receive eribulin alone or in combination with anlotinib. The primary efficacy endpoint was investigator-assessed progression-free survival (PFS). RESULTS: From June 2020 to April 2022, a total of 80 patients were randomly assigned to either eribulin monotherapy or eribulin plus anlotinib combination therapy, with 40 patients in each group. The data cut-off was 10 August 2022. The median PFS was 3.5 months [95% confidence interval (CI) 2.8-5.5 months] for eribulin and 5.1 months (95% CI 4.5-6.9 months) for eribulin plus anlotinib (hazard ratio = 0.56, 95% CI 0.32-0.98; P = 0.04). The objective response rates were 32.5% versus 52.5% (P = 0.07), respectively, and disease control rates were 67.5% versus 92.5% (P = 0.01), respectively. Patients <50 years of age, with an Eastern Cooperative Oncology Group performance status score of 0, visceral metastasis, number of treatment lines of four or more, hormone receptor negative (triple-negative), and HER2 low expression appeared to benefit more from combined treatment. The most common adverse events in both groups were leukopenia (n = 28, 70.0%, patients in the eribulin monotherapy group versus n = 35, 87.5%, patients in the combination therapy group), aspartate aminotransferase elevations (n = 28, 70.0%, versus n = 35, 87.5%), neutropenia (n = 25, 62.5%, versus n = 31, 77.5%), and alanine aminotransferase elevations (n = 25, 62.5%, versus n = 30, 75.0%). CONCLUSION: Eribulin plus anlotinib can be considered an alternative treatment option for HER2-negative locally advanced or metastatic breast cancer. Elsevier 2023-06-06 /pmc/articles/PMC10265607/ /pubmed/37285718 http://dx.doi.org/10.1016/j.esmoop.2023.101563 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Liu, B. Liu, L. Ran, J. Xie, N. Li, J. Xiao, H. Yang, X. Tian, C. Wu, H. Lu, J. Gao, J. Hu, X. Cao, M. Shui, Z. Hu, Z.-Y. Ouyang, Q. A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
title | A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
title_full | A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
title_fullStr | A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
title_full_unstemmed | A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
title_short | A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
title_sort | randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265607/ https://www.ncbi.nlm.nih.gov/pubmed/37285718 http://dx.doi.org/10.1016/j.esmoop.2023.101563 |
work_keys_str_mv | AT liub arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT liul arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT ranj arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT xien arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT lij arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT xiaoh arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT yangx arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT tianc arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT wuh arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT luj arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT gaoj arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT hux arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT caom arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT shuiz arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT huzy arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT ouyangq arandomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT liub randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT liul randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT ranj randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT xien randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT lij randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT xiaoh randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT yangx randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT tianc randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT wuh randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT luj randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT gaoj randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT hux randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT caom randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT shuiz randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT huzy randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer AT ouyangq randomizedtrialoferibulinmonotherapyversuseribulinplusanlotinibinpatientswithlocallyrecurrentormetastaticbreastcancer |